Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1425Carcinoma, Renal Cell 586Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 123Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 77Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 50Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 43Neuroblastoma 39Uterine Cervical Neoplasms 38Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Head and Neck Neoplasms 26Clear-cell metastatic renal cell carcinoma 26

Interventions

toripalimab 1liposomal doxorubicin 1disitamab vedotin 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Muscle Invasive Bladder Cancer × Genitourinary × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT04101812 2019-09-26

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Tianjin Medical University Second Hospital

Phase 2 Unknown
60 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡